Clarification | GenomeWeb



Due to an editing oversight, a quote from Mark Stolorow, executive director of Orchid Cellmark, was truncated in last week’s issue of BioInform. The full quote is as follows: “We have adequate quality assurance controls in place to help us identify and correct any foreseeable quality assurance contingency. If I knew that it weren’t, I would correct it, so we operate under the assumption that we have adequate controls in place, and in the 16 year history of our company here at our Germantown site, that has been the case.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.